Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
It is produced by modifying the Cterminus of the MTII scaffold replacing the terminal amide with a hydroxyl group yielding a related cyclic peptide with a distinct receptorselectivity profile while retaining the lactambridged, enzymatically stable architecture of its parent compound
You may request a free 15-minute consultation with Dr
Enhancing anticancer efficacy: xovoltib-loaded chitosan-tripolyphosphate nanoparticles for targeted drug delivery against MCF-7 breast cancer cells
Arch Intern Med 147:713-717
#AcuteDecompensation #ACLF #Inflammation #LiverDisease #GENFIT #G1090N *G1090N is an investigational drug candidate.* European Foundation for the Study of Chronic Liver Failure (EF CLIF), European Liver Patients' Association - ELPA Global Liver Institute American Liver Foundation To view or add a comment, sign in Following recent Phase 1 data that provided a solid foundation for advancing G1090N into Phase 2 proof-of-concept studies across the ACLF continuum, explore our latest scientific poster presented at AASLD 2025 to learn more about its active metabolite and earlier body of evidence
Because glutathione acts as an intracellular antioxidant without affecting incretin pathways, combining it with GLP-1 therapy is considered safe
US$ 20.15
US$ 29.70
US$ 25.93
US$ 25.41
US$ 29.11
